Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Citi
Medtronic
Argus Health
Queensland Health
Harvard Business School
Colorcon
Merck
Covington

Generated: September 18, 2018

DrugPatentWatch Database Preview

DrugPatentWatch Database Updates: New Patent Additions

« Back to Dashboard

DrugPatentWatch Database Updates: New Patent Additions

These are patents which have been reported by the FDA since the last major update; they are not yet in the main database.
Applicant Tradename Generic Name Dosage NDA Number Approval Date Type RLD Patent No. Product Substance Delist_Flag Patent Expiration Usecode Patented / Exclusive Use
Veroscience CYCLOSET bromocriptine mesylate TABLET 020866 001 May 5, 2009 RX Yes ➤ Try a Free Trial ➤ Try a Free Trial U-2384 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1 AND 10
Mannkind AFREZZA insulin recombinant human POWDER 022472 001 Jun 27, 2014 RX Yes ➤ Try a Free Trial ➤ Try a Free Trial U-2383 METHOD OF CONTROLLING GLYCEMIA IN A DIABETIC PATIENT WITH DELAYED OR PROLONGED FOOD ABSORPBTION BY ADMINISTERING 50 TO 75% OF A PREDETERMINED DOSE OF INSULIN-FDKP AT MEALTIME, AND ADMINISTERING REMAINDER OF DOSE 30-120 MINUTES AFTER BEGINNING OF MEAL
Mannkind AFREZZA insulin recombinant human POWDER 022472 002 Jun 27, 2014 RX Yes ➤ Try a Free Trial ➤ Try a Free Trial U-2383 METHOD OF CONTROLLING GLYCEMIA IN A DIABETIC PATIENT WITH DELAYED OR PROLONGED FOOD ABSORPBTION BY ADMINISTERING 50 TO 75% OF A PREDETERMINED DOSE OF INSULIN-FDKP AT MEALTIME, AND ADMINISTERING REMAINDER OF DOSE 30-120 MINUTES AFTER BEGINNING OF MEAL
Mannkind AFREZZA insulin recombinant human POWDER 022472 003 Apr 17, 2015 RX Yes ➤ Try a Free Trial ➤ Try a Free Trial U-2383 METHOD OF CONTROLLING GLYCEMIA IN A DIABETIC PATIENT WITH DELAYED OR PROLONGED FOOD ABSORPBTION BY ADMINISTERING 50 TO 75% OF A PREDETERMINED DOSE OF INSULIN-FDKP AT MEALTIME, AND ADMINISTERING REMAINDER OF DOSE 30-120 MINUTES AFTER BEGINNING OF MEAL
Ironshore Pharms JORNAY PM methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE 209311 001 Aug 8, 2018 RX Yes ➤ Try a Free Trial ➤ Try a Free Trial U-2357 METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
Applicant Tradename Generic Name Dosage NDA Number Approval Date Type RLD Patent No. Product Substance Delist_Flag Patent Expiration Usecode Patented / Exclusive Use

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Merck
Cipla
Daiichi Sankyo
McKinsey
Healthtrust
Federal Trade Commission
Citi
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.